订阅小程序
旧版功能

P86.16 Rationale of a Phase II Trial of Nivolumab Combined with Anlotinib in Advanced NSCLC Previously Treated with Immunotherapy

B. Han,B. Zhang,C. Shi,Z. Gao,H. Zhong,L. Xiong,A. Gu, W. Wang,T. Chu,W. Zhang, H. Wang,X. Zhang,R. Zhong

JOURNAL OF THORACIC ONCOLOGY（2021）

引用 0|浏览14
关键词
non-small cell lung cancer,checkpoint inhibitors,Anlotinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要